When Custom Synthesis Is the Right Path
Custom synthesis is appropriate when the required peptide sequence is novel, proprietary, or not available as a standard catalog item from a manufacturer’s existing product line. This covers a wide range of scenarios, from early-stage drug discovery candidates to modified versions of known peptides with altered stability or activity profiles.
Buyers should distinguish custom synthesis, which starts from a specific sequence provided by the buyer, from custom formulation, which may involve a manufacturer’s existing peptide combined into a specific delivery format; the two involve very different technical and commercial conversations with a manufacturer.
Sequence Design and Feasibility Review
Before committing to a full production run, most manufacturers conduct a feasibility review of the submitted sequence, identifying difficult couplings, aggregation-prone regions, or solubility concerns that could affect synthesis success or final yield. This review often results in a small-scale feasibility batch before a larger commercial quantity is committed.
Buyers should expect to share the full intended sequence for this review; manufacturers generally cannot provide a meaningful feasibility assessment or accurate quote without it, and requests to quote based on partial sequence information typically produce unreliable estimates.
Timeline Expectations for Custom Work
Custom sequences typically take longer than catalog peptides, since there is no existing validated process to draw on, and the manufacturer must develop and validate a synthesis route specific to the sequence. Timelines of several weeks to a few months are common depending on sequence complexity, required scale, and whether the manufacturer needs to develop novel purification conditions.
Building this timeline into project planning early, rather than treating custom synthesis as interchangeable with catalog ordering, prevents downstream schedule pressure on research or development timelines that depend on the material.
Intellectual Property Considerations
Sharing a proprietary sequence with a manufacturer requires a confidentiality agreement covering not just the sequence itself but any process knowledge the manufacturer develops while synthesizing it. Buyers should clarify upfront whether the manufacturer retains rights to use any process improvements developed during the engagement for other clients, since default terms vary between manufacturers.
For sequences with significant commercial value, involving legal counsel in reviewing the confidentiality and IP terms of a custom synthesis agreement before sharing the sequence is a reasonable and common precaution.